Related Experiment Video
Updated: Nov 7, 2025

Author Spotlight: A Novel Method for Comprehensive Cell Component Analysis of Cerebral Blood Clots
Published on: July 21, 2023
Arterial Thrombotic Sequalae After Covid-19: Mind the Gap
Maria Pia Borrelli1, Adelaide Buora1, Paola Scrivere1
1Unit of Vascular and Endovascular Surgery, General Surgery Department, University Hospital of Udine, Udine, Italy.
Abstract:
Investigations have shown that infection from the severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) is responsible also for initiating severe inflammatory responses that can lead macrovascular and microvascular thrombosis. Several studies have already described acute limb ischemia and peripheral arterial disease in critically ill patients with Coronavirus disease 2019 (Covid-19), as well as coronary artery disease and ischemic stroke as a manifestation usually associated with respiratory distress. However, what still remains unclear is how long inflammation and thrombotic derangements can last after recovery from the symptoms of Covid-19. Hence, in this article we report 3 cases of arterial thrombotic sequalae after this viral infection. To the best of our knowledge, this is the first cases' series that had described different delayed vascular arterial complications, which occurred after the index infection, with a negative nasopharyngeal swab and Covid-19 systemic symptoms resumption. A better understanding of the coagulopathy in Covid-19 could have an essential role to guide prevention and treatment of arterial thromboembolic events, both during and after the viral infection. Further investigations are required to confirm these data and to estabilish the type, dose and duration of anticoagulant/antiplatelet therapy not just during but also after Covid-19 infection.
Related Concept Videos
Venous Thrombosis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Endocarditis II: Clinical Features of Infective Endocarditis
Venous Thrombosis III: Interprofessional Care
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Anticoagulant Drugs: Low-Molecular-Weight Heparins

